 The FDA grants Breakthrough Therapy Designation to Valneva SEs NASDAQ: VALN single-shot chikungunya vaccine candidate, VLA1553. This new U.S. milestone comes in addition to the FDA Fast Track designation and the European Medicines Agencys PRIME designation, which the Company received in December 2018 and in October 2020, respectively. 